Liver fibrosis progression at autopsy in injecting drug users infected by hepatitis C: A longitudinal long-term cohort study

Journal of Hepatology

Volumn 60, Issue 2, 2014, Pages 260-266

  Kielland, Knut Boe ^a,b   Delaveris, Gerd Jorunn Møller ^c,d   Rogde, Sidsel ^c,d   Eide, Tor Jacob ^d,e   Amundsen, Ellen J ^f   Dalgard, Olav ^d,g  

^a INNLANDET HOSPITAL TRUST   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f NORWEGIAN INSTITUTE FOR ALCOHOL AND DRUG RESEARCH   (Norway)

^g AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cirrhosis; Drug abuse; HCV; Hepatitis C; IDU; Liver fibrosis; Longitudinal; METAVIR; PWID; Steatosis

Indexed keywords

VIRUS RNA;

ADULT; ARTICLE; AUTOPSY; COHORT ANALYSIS; DISEASE COURSE; DRUG ABUSE; DRUG DEPENDENCE TREATMENT; DRUG USE; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; INJECTING DRUG USER; LIVER; LIVER CIRRHOSIS; LIVER FIBROSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT;

ALANINE TRANSAMINASE; ALT; ANTI-HBC; ANTI-HCV; CHC; CHRONIC HEPATITIS C; CI; CIRRHOSIS; CONFIDENCE INTERVAL; DRUG ABUSE; HBSAG; HCC; HCV; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C; HEPATITIS C ANTIBODY; HEPATITIS C VIRUS; HEPATOCELLULAR CARCINOMA; IDU; INJECTING DRUG USER; INTERQUARTILE RANGE; IQR; LIVER FIBROSIS; LONGITUDINAL; METAVIR; PWID; RIBONUCLEIC ACID; RNA; STEATOSIS;

ADULT; AUTOPSY; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NORWAY; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84892530825     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.09.022     Document Type: Article

References (31)

1. K.B. Kielland, and J.C. Siebke Hepatitis A-, B- and C-markers among Norwegian drug addicts in the period 1975-89 Tidsskr Nor Laegeforen 111 1991 821 824
2. F. Cholet, J.B. Nousbaum, M. Richecoeur, E. Oger, J.M. Cauvin, and N. Lagarde et al. Factors associated with liver steatosis and fibrosis in chronic hepatitis C patients Gastroenterol Clin Biol 28 2004 272 278
3. L.B. Seeff, F.B. Hollinger, H.J. Alter, E.C. Wright, C.M. Cain, and Z.J. Buskell et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study Hepatology 33 2001 455 463
4. E. Kenny-Walsh Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group N Engl J Med 340 1999 1228 1233
5. M. Wiese, K. Grungreiff, W. Guthoff, M. Lafrenz, U. Oesen, and H. Porst Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany-a 25-year multicenter study J Hepatol 43 2005 590 598
6. D. Posthouwer, M. Makris, T.T. Yee, K. Fischer, J.J. Van Veen, and A. Griffioen et al. Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study Blood 109 2007 3667 3671
7. P. Ferenci, S. Ferenci, C. Datz, I. Rezman, W. Oberaigner, and R. Strauss Morbidity and mortality in paid Austrian plasma donors infected with hepatitis C at plasma donation in the 1970s J Hepatol 47 2007 31 36
8. G. Ostapowicz, S.J. Bell, and P.V. Desmond Severity of liver disease in hepatitis C infection contracted through injecting drug use Aust N Z J Med 29 1999 776 781
9. R. Rai, L.E. Wilson, J. Astemborski, F. Anania, M. Torbenson, and C. Spoler et al. Severity and correlates of liver disease in hepatitis C virus-infected injection drug users Hepatology 35 2002 1247 1255
10. S.D. Ryder, W.L. Irving, D.A. Jones, K.R. Neal, and J.C. Underwood Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study Gut 53 2004 451 455
11. A. John-Baptiste, M. Krahn, J. Heathcote, A. Laporte, and G. Tomlinson The natural history of hepatitis C infection acquired through injection drug use: meta-analysis and meta-regression J Hepatol 53 2010 245 251
12. I. Maremmani, P.P. Pani, A. Mellini, M. Pacini, G. Marini, and M. Lovrecic et al. Alcohol and cocaine use and abuse among opioid addicts engaged in a methadone maintenance treatment program J Addict Dis 26 2007 61 70
13. A. Nyamathi, A. Cohen, M. Marfisee, S. Shoptaw, B. Greengold, and C.V. De et al. Correlates of alcohol use among methadone-maintained adults Drug Alcohol Depend 101 2009 124 127
14. K.B. Kielland, K. Skaug, E.J. Amundsen, and O. Dalgard All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study J Hepatol 58 2013 31 37
15. J.A. Garson, C.J. Ring, and P.W. Tuke Improvement of HCV genome detection with "short" PCR products Lancet 338 1991 1466 1467
16. T. Poynard, P. Bedossa, and P. Opolon Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups Lancet 349 1997 825 832
17. R. Sobesky, P. Mathurin, F. Charlotte, J. Moussalli, M. Olivi, and M. Vidaud et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group Gastroenterology 116 1999 378 386
18. M.V. Reggiardo, F. Fay, M. Tanno, G. Garcia-Camacho, O. Bottaso, and S. Ferretti et al. Natural history of hepatitis C virus infection in a cohort of asymptomatic post-transfused subjects Ann Hepatol 11 2012 658 666
19. P.Y. Bochud, S. Bibert, Z. Kutalik, E. Patin, J. Guergnon, and B. Nalpas et al. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes Hepatology 55 2012 384 394
20. H.H. Thein, Q. Yi, G.J. Dore, and M.D. Krahn Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression Hepatology 48 2008 418 431
21. S. Barrett, J. Goh, B. Coughlan, E. Ryan, S. Stewart, and A. Cockram et al. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection Gut 49 2001 423 430
22. S. Darke, S. Kaye, and J. Duflou Systemic disease among cases of fatal opioid toxicity Addiction 101 2006 1299 1305
23. P.B. Christensen, B. Kringsholm, J. Banner, J.L. Thomsen, S. Cowan, and G.F. Stein et al. Surveillance of HIV and viral hepatitis by analysis of samples from drug related deaths Eur J Epidemiol 21 2006 383 387
24. P. Halfon, G. Penaranda, F. Carrat, P. Bedossa, M. Bourliere, and D. Ouzan et al. Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV-HCV co-infected patients Aliment Pharmacol Ther 30 2009 61 70
25. G. Colloredo, M. Guido, A. Sonzogni, and G. Leandro Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease J Hepatol 39 2003 239 244
26. P. Bedossa, D. Dargere, and V. Paradis Sampling variability of liver fibrosis in chronic hepatitis C Hepatology 38 2003 1449 1457
27. A. Regev, M. Berho, L.J. Jeffers, C. Milikowski, E.G. Molina, and N.T. Pyrsopoulos et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection Am J Gastroenterol 97 2002 2614 2618
28. T. Poynard, G. Lenaour, J.C. Vaillant, F. Capron, M. Munteanu, and D. Eyraud et al. Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis Clin Gastroenterol Hepatol 10 2012 657 663
29. B.M. Mathers, L. Degenhardt, B. Phillips, L. Wiessing, M. Hickman, and S.A. Strathdee et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review Lancet 372 2008 1733 1745
30. P.Y. Bochud, T. Cai, K. Overbeck, M. Bochud, J.F. Dufour, and B. Mullhaupt et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C J Hepatol 51 2009 655 666
31. O. Dalgard, A. Egeland, R. Ervik, K. Vilimas, K. Skaug, and T.W. Steen Risk factors for hepatitis C among injecting drug users in Oslo Tidsskr Nor Laegeforen 129 2009 101 104